Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rimonabant (SR141716), SR141716, Acomplia
rimonabant · 19 trials · 12 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rimonabant |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Rimonabant | EXPERIMENTAL | Rimonabant 20 mg once daily with mild hypocaloric diet |
| Placebo | PLACEBO_COMPARATOR | Placebo (for Rimonabant) once daily with mild hypocaloric diet |
| Name | Type | Description |
|---|---|---|
| Rimonabant | DRUG | White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast |
| Placebo | DRUG | Matching placebo tablets. Once daily before breakfast |
| Rimonabant (SR141716) | DRUG | - |
| Placebo (for Rimonabant) | DRUG | Tablet, oral administration |
| Mild hypocaloric diet | OTHER | Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity |
List of Inclusion and Exclusion criteria: Inclusion Criteria: * History of Type 2 diabetes * HbA1c between 7% to 9% (inclusive) * BMI ≥ 27kg/m² and BMI ≤ 40kg/m² * Currently taking Metformin and Sulfonylurea. Exclusion Criteria: * Uncontrolled serious psychiatric illness such as major depression...
Rimonabant has been studied for obesity, metabolic syndrome, dyslipidemia, coronary atherosclerosis, and smoking cessation, including maintenance of smoking cessation. It was also evaluated in overweight or obese patients with type 2 diabetes. These uses were investigated in clinical trials; rimonabant is not approved for marketing.
Rimonabant targets CNR1, the cannabinoid receptor type 1, acting as an antagonist. By blocking this receptor, it was intended to reduce appetite and modulate metabolic and cardiovascular risk factors. This mechanism was explored across obesity, smoking cessation, and cardiometabolic indications.
Rimonabant was developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the clinical development program, including Phase 3 trials in obesity, smoking cessation, and type 2 diabetes.
Rimonabant reached Phase 3 clinical development. Eight trials are registered, all completed, with no active trials. It is an investigational small molecule and has not been approved by the FDA for any indication.
Rimonabant has been studied in completed Phase 3 trials including NCT00546325 (REASSURE) in type 2 diabetes, NCT00481975 in obesity and eating disorders, NCT00481923 in obesity, and NCT00464256 in smoking cessation. Across eight trials, total enrollment was 8,245 participants.
Yes, rimonabant is also known as SR141716. SR141716 is the compound identifier used for rimonabant, a small molecule CNR1 antagonist developed by Sanofi.